Effect of PNPLA3 rs738409 variant (I148 M) on hepatic steatosis, necroinflammation, and fibrosis in Japanese patients with chronic hepatitis C

Journal of Gastroenterology

Volumn 50, Issue 8, 2015, Pages 887-893

  Yasui, Kohichiroh ^a   Kawaguchi, Takahisa ^b   Shima, Toshihide ^c   Mitsuyoshi, Hironori ^a   Seki, Kojiro ^c   Sendo, Rei ^c   Mizuno, Masayuki ^c   Itoh, Yoshito ^a   Matsuda, Fumihiko ^b   Okanoue, Takeshi ^c  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Saiseikai Imperial Gift Foundation Inc Saiseikai Suita Hospital   (Japan)

Author keywords

Fibrosis; Hepatitis C; PNPLA3; Single nucleotide polymorphism; Steatosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; ADIPONUTRIN, HUMAN; MEMBRANE PROTEIN; TRIACYLGLYCEROL LIPASE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALCOHOL LIVER DISEASE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CHRONIC HEPATITIS C; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN TISSUE; INFLAMMATION; JAPANESE (PEOPLE); LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NECROINFLAMMATION; NONALCOHOLIC FATTY LIVER; PATATIN LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 GENE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE COUNT; AGED; FATTY LIVER; GENETIC PREDISPOSITION; GENETICS; LIVER; LIVER CIRRHOSIS; NECROSIS; PATHOLOGY; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; CROSS-SECTIONAL STUDIES; FATTY LIVER; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEPATITIS C, CHRONIC; HUMANS; LIPASE; LIVER; LIVER CIRRHOSIS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NECROSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; SEVERITY OF ILLNESS INDEX;

EID: 84938867980     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-014-1018-z     Document Type: Article

References (44)

1. Poynard T, McHutchison J, Manns M, et al. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology. 2003;38:481–92.
2. Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology. 2006;130:1636–42.
3. Negro F. Mechanisms and significance of liver steatosis in hepatitis C virus infection. World J Gastroenterol. 2006;12:6756–65.
4. Rubbia-Brandt L, Quadri R, Abid K, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol. 2000;33:106–15.
5. Yasui K, Harano Y, Mitsuyoshi H, et al. Steatosis and hepatic expression of genes regulating lipid metabolism in Japanese patients infected with hepatitis C virus. J Gastroenterol. 2010;45:95–104.
6. Wright M, Goldin R, Fabre A, et al. Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross-sectional and longitudinal study. Gut. 2003;52:574–9.
7. Missiha SB, Ostrowski M, Heathcote EJ. Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. Gastroenterology. 2008;134:1699–714.
8. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40:1461–5.
9. Valenti L, Al-Serri A, Daly AK, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148 M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2010;51:1209–17.
10. Rotman Y, Koh C, Zmuda JM, et al. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology. 2010;52:894–903.
11. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148 M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology. 2011;53:1883–94.
12. Tian C, Stokowski RP, Kershenobich D, et al. Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet. 2010;42:21–3.
13. Stickel F, Buch S, Lau K, et al. Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in Caucasians. Hepatology. 2011;53:86–95.
14. Trépo E, Gustot T, Degré D, et al. Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease. J Hepatol. 2011;55:906–12.
15. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–9.
16. Kawaguchi T, Sumida Y, Umemura A, et al. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. PLoS One. 2012;7:e38322.
17. Valenti L, Rumi M, Galmozzi E, et al. Patatin-like phospholipase domain-containing 3 I148 M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology. 2011;53:791–9.
18. Trépo E, Pradat P, Potthoff A, et al. Impact of patatin-like phospholipase-3 (rs738409 C > G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology. 2011;54:60–9.
19. Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus, Seino Y, Nanjo K, et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig. 2010;1:212–28.
20. Simmonds P, Alberti A, Alter HJ, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology. 1994;19:1321–4.
21. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349:825–32.
22. Cai T, Dufour JF, Muellhaupt B, et al. Viral genotype-specific role of PNPLA3, PPARG, MTTP, and IL28B in hepatitis C virus-associated steatosis. J Hepatol. 2011;55:529–35.
23. Sato M, Kato N, Tateishi R, et al. Impact of PNPLA3 polymorphisms on the development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Hepatol Res. 2014;44:E137–44.
24. Moritou Y, Ikeda F, Iwasaki Y, et al. Impact of comorbid hepatic steatosis on treatment of chronic hepatitis C in Japanese patients and the relationship with genetic polymorphism of IL28B, PNPLA3 and LDL receptor. Acta Med Okayama. 2014;68:17–22.
25. Nakamura M, Kanda T, Nakamoto S, et al. No correlation between PNPLA3 rs738409 genotype and fatty liver and hepatic cirrhosis in Japanese patients with HCV. PLoS One. 2013;8:e81312.
26. Nischalke HD, Berger C, Luda C, et al. The PNPLA3 rs738409 148 M/M genotype is a risk factor for liver cancer in alcoholic cirrhosis but shows no or weak association in hepatitis C cirrhosis. PLoS One. 2011;6:e27087.
27. Falleti E, Fabris C, Cmet S, et al. PNPLA3 rs738409C/G polymorphism in cirrhosis: relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence. Liver Int. 2011;31:1137–43.
28. Trépo E, Nahon P, Bontempi G, et al. Association between the PNPLA3 (rs738409 C > G) variant and hepatocellular carcinoma: Evidence from a meta-analysis of individual participant data. Hepatology. 2014;59:2170–7.
29. Müller T, Buch S, Berg T, et al. Distinct, alcohol-modulated effects of PNPLA3 genotype on progression of chronic hepatitis C. J Hepatol. 2011;55:732–3.
30. Valenti L, Colombo M, Fargion S. Modulation of the effect of PNPLA3 I148 M mutation on steatosis and liver damage by alcohol intake in patients with chronic hepatitis C. J Hepatol. 2011;55:1470–1.
31. Haber MM, West AB, Haber AD, et al. Relationship of aminotransferases to liver histological status in chronic hepatitis C. Am J Gastroenterol. 1995;90:1250–7.
32. Okanoue T, Makiyama A, Nakayama M, et al. A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase. J Hepatol. 2005;43:599–605.
33. Dunn W, O’Neil M, Zhao J, et al. Donor PNPLA3 rs738409 genotype affects fibrosis progression in liver transplantation for hepatitis C. Hepatology. 2014;59:453–60.
34. He S, McPhaul C, Li JZ, et al. A sequence variation (I148 M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem. 2010;285:6706–15.
35. Huang Y, He S, Li JZ, et al. A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc Natl Acad Sci USA. 2010;107:7892–7.
36. Lake AC, Sun Y, Li JL, et al. Expression, regulation, and triglyceride hydrolase activity of Adiponutrin family members. J Lipid Res. 2005;46:2477–87.
37. Li JZ, Huang Y, Karaman R, et al. Chronic overexpression of PNPLA3 I148 M in mouse liver causes hepatic steatosis. J Clin Invest. 2012;122:4130–44.
38. Pirazzi C, Adiels M, Burza MA, et al. Patatin-like phospholipase domain-containing 3 (PNPLA3) I148 M (rs738409) affects hepatic VLDL secretion in humans and in vitro. J Hepatol. 2012;57:1276–82.
39. Pingitore P, Pirazzi C, Mancina RM, et al. Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148 M mutation results in loss of function. Biochim Biophys Acta. 2014;1841:574–80.
40. Pirazzi C, Valenti L, Motta BM, et al. PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells. Hum Mol Genet. 2014;23:4077–85.
41. Kumari M, Schoiswohl G, Chitraju C, et al. Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase. Cell Metab. 2012;15:691–702.
42. Kumashiro N, Yoshimura T, Cantley JL, et al. Role of patatin-like phospholipase domain-containing 3 on lipid-induced hepatic steatosis and insulin resistance in rats. Hepatology. 2013;57:1763–72.
43. Chen W, Chang B, Li L, Chan L. Patatin-like phospholipase domain-containing 3/adiponutrin deficiency in mice is not associated with fatty liver disease. Hepatology. 2010;52:1134–42.
44. Basantani MK, Sitnick MT, Cai L, et al. Pnpla3/Adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome. J Lipid Res. 2011;52:318–29.